Antibodies Produced by CLL Phenotype B Cells in Patients With Myasthenia Gravis Are Not Directed Against Neuromuscular Endplates.
Florian IngelfingerMichael KramerMirjam LutzCorinne C WidmerLuca PiccoliStefanie KreutmairTobias WertheimerMark WoodhallPatrick WatersFederica SallustoAntonio LanzavecchiaSarah MundtBurkhard BecherBettina SchreinerPublished in: Neurology(R) neuroimmunology & neuroinflammation (2023)
This is a single case study and provides Class IV evidence that obinutuzumab is safe to use in patients with MG.